^
    9ms
    BP1002-102-AML: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=48, Recruiting, Bio-Path Holdings, Inc. | Trial completion date: Sep 2024 --> Sep 2027 | Trial primary completion date: Mar 2024 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    decitabine • BP1002
    9ms
    BP1002-101-Lymph: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Bio-Path Holdings, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Apr 2025 | Trial primary completion date: Sep 2024 --> Apr 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    BP1002
    almost2years
    A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=30, Recruiting, Bio-Path Holdings, Inc. | Trial completion date: Jan 2025 --> Jan 2026
    Trial completion date • Metastases
    |
    BCL2 expression
    |
    BP1002
    2years
    A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=30, Recruiting, Bio-Path Holdings, Inc. | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression
    |
    BP1002
    3years
    A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=48, Recruiting, Bio-Path Holdings, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    decitabine • BP1002
    over3years
    A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Bio-Path Holdings, Inc. | Initiation date: Apr 2022 --> Jul 2022
    Trial initiation date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    decitabine • BP1002
    over3years
    A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=30, Recruiting, Bio-Path Holdings, Inc. | Trial completion date: Aug 2022 --> Jan 2024 | Trial primary completion date: Feb 2022 --> Sep 2023
    Trial completion date • Trial primary completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression
    |
    BP1002
    over3years
    A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Bio-Path Holdings, Inc. | Initiation date: Jan 2022 --> Apr 2022
    Trial initiation date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    decitabine • BP1002
    almost4years
    A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Bio-Path Holdings, Inc.
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    decitabine • BP1002
    over4years
    [VIRTUAL] The combination of liposomal Bcl-2 antisense oligonucleotide (BP1002) with decitabine is efficacious in venetoclax-resistant cells (AACR 2021)
    Our data indicate that, despite expressing higher levels of anti-apoptotic proteins, venetoclax-resistant cells are sensitive to the BP1002 plus decitabine combination. These promising preclinical results suggest that the BP1002 plus decitabine combination is a potential treatment for patients who have relapsed from frontline venetoclax-based therapies.
    IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1)
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • decitabine • BP1002
    almost5years
    A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=30, Recruiting, Bio-Path Holdings, Inc. | Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
    Clinical • Trial completion date • Trial primary completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression
    |
    BP1002